Сравнение на методи
Прегледайте избраните методи един до друг; редовете с разлики са откроени.
| Скала за качеството на живот, свързано със здравето при ГЕРБ× | Индекс на основните симптоми на гастропареза (GCSI)× | |
|---|---|---|
| Област | Гастроентерология | Гастроентерология |
| Семейство | Process / pipeline | Process / pipeline |
| Година на възникване≠ | 1996 | 2003 |
| Създател≠ | Velanovich, V., Zhang, Y., Hollis, J. B., et al. | Revicki, D. A., Rentz, A. M., Dubois, D., et al. |
| Тип | Self-report | Self-report |
| Основополагащ източник≠ | Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873. link ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ |
| Други названия≠ | GERD-HRQL, GERD-HRQoL | GCSI |
| Свързани | 4 | 4 |
| Резюме≠ | The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice. | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. |
| ScholarGateНабор от данни ↗ |
|
|